Boston Scientific Corporation (NYSE:BSX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Boston Scientific Corporation (NYSE:BSX) have been assigned an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, twenty have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $109.4348.

BSX has been the topic of several research analyst reports. Oppenheimer dropped their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Needham & Company LLC dropped their price target on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, February 2nd. Robert W. Baird dropped their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th.

Boston Scientific Stock Performance

NYSE BSX opened at $74.72 on Tuesday. The firm has a market capitalization of $110.76 billion, a P/E ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The firm’s fifty day moving average price is $90.56 and its two-hundred day moving average price is $97.35. Boston Scientific has a 1 year low of $72.69 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the business earned $0.70 EPS. Boston Scientific’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently bought and sold shares of the business. Steph & Co. acquired a new position in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. bought a new stake in shares of Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter worth $26,000. Finally, Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.